Mylan's Morgantown Plant To Shut Down In JulyThe Mylan plant in Morgantown will shut down on July 31 and 1,500 employees will lose their jobs.
Coronavirus In Pittsburgh Area: Mylan To Restart Production Of Drug Considered Possible Treatment For VirusMylan Pharmaceuticals is restarting the production of a drug considered as a possible treatment for coronavirus.
Xanax Recalled Nationwide Due To Possible 'Foreign Substance'Mylan Pharmaceuticals is pulling one lot of Xanax from pharmacy shelves nationwide because of what the company said is "the potential presence of a foreign substance."
Families Turning To EpiPen Alternatives Due To Year-Long ShortageFor over a year, families have been struggling to overcome a shortage of EpiPens, a life-saving shot for those with severe allergies.
Pfizer Buying Canonsburg-Based Mylan, New Company To Run Operations In PittsburghPfizer is buying Mylan in an all-stock deal and combining the $10 billion generic pharmaceutical company with its own off-patent branded and generic business.
Mylan's CEO Takes Lessons Learned From EpiPen Controversy Into Launching Of New DrugMylan Labs is about to launch a new drug that could revolutionize the way cancer is treated, and it could make it cheaper.
Shareholders Urge Rejection Of Mylan Directors, CompensationSome big pension funds are attempting to block the re-election of a number of Mylan board members
Anti-Allergy Medicine EpiPen Recall Expands To U.S.A recall of the emergency anti-allergy medicine EpiPen is expanding to the U.S. and other markets in North America, Europe, Asia and South America because the allergy shots may not work.
Defective Part Prompts Recall Of 80,000 EpiPensFour batches of EpiPens are being recalled because they may fail to activate or require increased force.
Mylan CEO Wants To Be ‘Catalyst For Change’ In Pharmaceutical PricingPharmaceutical giant Mylan, which is based in Canonsburg, was at the center of criticism last year over rising drug prices.
Mylan To Purchase Cold-Eeze Lozenge BrandThe Pennsylvania-based maker of Cold-Eeze throat lozenges has announced that it has sold the brand to another pharmaceutical company for $50 million.